NPPA seeks cut in prices of anti-cancer medications Sub :Sci Sec: Health Context: The National Pharmaceutical Pricing Authority (NPPA) has instructed manufacturers to lower the maximum retail prices of three significant anti-cancer drugs: Trastuzumab, Osimertinib, and Durvalumab. This action aligns with the government’s goal of ensuring that essential medicines are available at affordable […]